(8S,9S,10R,13R,14S,17R)-1,1,2-trihydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-6,7,8,9,11,12,14,15,16,17-decahydro-2H-cyclopenta[a]phenanthren-3-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (8S,9S,10R,13R,14S,17R)-1,1,2-trihydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-6,7,8,9,11,12,14,15,16,17-decahydro-2H-cyclopenta[a]phenanthren-3-one
• 化学式: C₂₇H₄₄O₄
• 分子量: 432.6
• InChiKey: HNWYTVAFOSUMJY-AXFZYESXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Compound and method for the treatment and diagnosis of neurodegenerative conditions
  申请人：SWANSEA UNIVERSITY

  公开号：US10226475B2

  公开（公告）日：2019-03-12

  A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. In particular, the reagent is a cholestenoic acid of a particular form, such as 3β,7α-dihydroxycholest-5-en-26-oic (3β,7α-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention.

  一种选自胆烯酸或胆烯酸生物合成或代谢途径中酶的抑制剂的试剂，用于治疗神经退行性疾病。特别是，该试剂是一种特殊形式的胆甾烯酸，如 3β,7α-二羟基胆甾烯-5-烯-26-酸（3β,7α-diHCA），以前与神经组织或 CSF 无关。本发明还包括药物组合物、治疗或预防神经退行性疾病的方法以及诊断方法和新型生物标记物。
• COMPOUND AND METHOD FOR THE TREATMENT OF NEURODEGENERATIVE CONDITIONS
  申请人：Swansea University

  公开号：EP2961400B1

  公开（公告）日：2017-11-01
• COMPOUND AND METHOD FOR THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE CONDITIONS
  申请人：Swansea University

  公开号：EP2961400A2

  公开（公告）日：2016-01-06
• METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS
  申请人：PEPSIS LIMITED

  公开号：US20210148933A1

  公开（公告）日：2021-05-20

  The invention concerns a method and assay for qualifying equine laminitis disease status in a subject by measuring specific biomarkers, comparing the level of said biomarker to a control level; and correlating the measurement with laminitis disease status, wherein a statistically relevant elevated level of said biomarker is present in said sample relative to said control level. The invention further relates to immuno-based methods and assays for detecting toxins relevant to laminitis and to the use of antibodies for assay and diagnostic purposes.
• [EN] COMPOUND AND METHOD FOR THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE CONDITIONS<br/>[FR] COMPOSÉ ET PROCÉDÉ POUR LE TRAITEMENT ET LE DIAGNOSTIC D'ÉTATS NEURODÉGÉNÉRATIFS
  申请人：UNIV SWANSEA

  公开号：WO2014132052A2

  公开（公告）日：2014-09-04

  A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. In particular, the reagent is a cholestenoic acid of a particular form, such as 3β,7α-dihydroxycholest-5 -en-26-oic (3β,7α-di HCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention.